• Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Events
  • Members
  • Specialists
  • Media
  • Clinical Trials
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Impact ISPOR
  • Observational Study
  • More
    • Home
    • Welcome
    • CAD & Treatments
    • Donation
    • Resources
    • Webinar Resources
    • Register Web Series
    • Latest News & Events
    • Members
    • Specialists
    • Media
    • Clinical Trials
    • Our Stories
    • Stay In The Know
    • Medical Advisors
    • Contact Us
    • Privacy & Policies
    • E-Learning Education
    • Impact ISPOR
    • Observational Study
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • Welcome
  • CAD & Treatments
  • Donation
  • Resources
  • Webinar Resources
  • Register Web Series
  • Latest News & Events
  • Members
  • Specialists
  • Media
  • Clinical Trials
  • Our Stories
  • Stay In The Know
  • Medical Advisors
  • Contact Us
  • Privacy & Policies
  • E-Learning Education
  • Impact ISPOR
  • Observational Study

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Enjaymo Treatment

Download PDF

Enjaymo

FDA approves Enjaymo™ (sutimlimab-jome), first  treatment for use in patients with cold agglutinin disease. Enjaymo is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system.

Find out more

FDA Approves Enjaymo

Download PDF

Copyright © 2022 Cold Agglutinin Disease Foundation - All Rights Reserved.

Privacy & Policies

Contact Us: info@cadfadvocacy.org

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept